drugset
drugset / Trial / NCT03437603

Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation

NCT03437603 ↗

Phase 2 Unknown 20 enrolled The First Affiliated Hospital of Soochow University
NaSingle-groupOpen-labelTreatment

Summary

To investigate the efficacy and safety for secondary poor graft function (PGF) post allogeneic hematopoietic stem cell transplantation (allo-HSCT). The primary objective is the hematologic response rate. Secondary objectives include: (1) incidence and severity of adverse events; (2) overall survival (OS), and disease-free survival(DFS).

Timeline

Start
2018-02
Primary completion
2019-01
Completion
2020-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule 50 mg —
Subject Eltrombopag Small molecule 75 mg —

Indications

No indication recorded.